DPT-IPV-Hib vaccine (MT-2355) / Mitsubishi Tanabe, Biken - LARVOL DELTA

Immunogenicity and safety of adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants ≥ 2 and < 43 months of Age: A phase III, multicenter, active controlled, assessor-blinded, randomized, parallel-group study. (PubMed, Vaccine) - "A single-agent Gobik, the first DPT-IPV-Hib pentavalent vaccine approved in Japan, was confirmed to simultaneously provide primary and booster immunizations against Hib infection, pertussis, diphtheria, tetanus, and poliomyelitis and to have a preventive effect and safety comparable to concomitant vaccination with Hib (ActHIB®) and DPT-IPV quadrivalent vaccine (Tetrabik)."

Journal • P3 data • Infectious Disease • Influenza • Pertussis • Respiratory Diseases • Tetanus

First Report of Pectobacterium parmentieri Causing Blackleg on Potato in Inner Mongolia, China. (PubMed, Plant Dis) - "The 16S rRNA gene sequences of four isolates (GenBank accession numbers: MN626412, MN626449, MN625916, and MT235556) showed more than 99% sequence identity to Pectobacterium parmentieri type strain RNS 08-42-1A (NR_153752.1) (Fig...To our knowledge, this is the first report of blackleg of potato caused by Pectobacterium parmentieri in Inner Mongolia, China. We believe that this report will draw attention to the identification of this pathogen, which is essential to disease management."

Journal

Confirmatory Study of BK1310 in Healthy Infants (clinicaltrials.gov) - P3; N=267; Completed; Sponsor: Mitsubishi Tanabe Pharma Corporation; Active, not recruiting ➔ Completed

Clinical • Trial completion • CNS Disorders • Infectious Disease • Respiratory Diseases • Tetanus

Confirmatory Study of BK1310 in Healthy Infants (clinicaltrials.gov) - P3; N=260; Active, not recruiting; Sponsor: Mitsubishi Tanabe Pharma Corporation; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Confirmatory Study of BK1310 in Healthy Infants (clinicaltrials.gov) - P3; N=260; Recruiting; Sponsor: Mitsubishi Tanabe Pharma Corporation; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Confirmatory Study of BK1310 in Healthy Infants (clinicaltrials.gov) - P3; N=260; Not yet recruiting; Sponsor: Mitsubishi Tanabe Pharma Corporation

Clinical • New P3 trial

Phase 3 Study of BK1310 in Healthy Infants (clinicaltrials.gov) - P3; N=370; Completed; Sponsor: Mitsubishi Tanabe Pharma Corporation; Active, not recruiting ➔ Completed

Clinical • Trial completion

Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants (clinicaltrials.gov) - P3; N=33; Completed; Sponsor: Mitsubishi Tanabe Pharma Corporation; Active, not recruiting ➔ Completed; Trial completion date: Dec 2018 ➔ Aug 2018

Clinical • Trial completion • Trial completion date